
Research articles


Every FDA Oncology Approval Notice in October 2026

How to Build an Indication-Level Competitive Landscape

Four Alzheimer Drug Readouts to Watch at CTAD 2026

Q3 2026 CBER Approvals for Direct Patient Use

Two Phase 3 CLDN18.2 ADC Readouts at ESMO 2026

WCLC 2026 SCLC Phase 3 Results: Two B7-H3 ADCs and MAVERICK

Q3 2026 Nasdaq Drug-Developer IPOs Above $100 Million
